Danyelle M Townsend1, Kenneth D Tew. 1. Department of Pharmaceutical and Biomedical Sciences, Medical University of South Carolina, 173 Ashley Avenue, P.O. Box 250505, Charleston, SC 29425, USA.
Abstract
NOV-002 is a novel therapeutic agent in development for oncology indications used in combination with chemotherapy. Clinical trials in Russia and the USA have demonstrated clinical activity and the present focus is on non-small cell lung cancer (NSCLC) patients. The active component of the drug is oxidized glutathione (GSSG) and this imparts multiple effects upon redox pathways both at the cell surface and inside the cell. The drug induces S-glutathionylation of some proteins and impacts kinase/phosphatase regulated signaling pathways. Induction of myeloproliferation is believed to contribute to the clinical advantages provided by NOV-002 that include improved tolerance of chemotherapy and increased survival.
NOV-002 is a novel therapeutic agent in development for oncology indications used in combination with chemotherapy. Clinical trials in Russia and the USA have demonstrated clinical activity and the present focus is on non-small cell lung cancer (pan class="Disease">NSCLC) patients. The active component of the drug is oxidized glutathione (GSSG) and this imparts multiple effects upon redox pathways both at the cell surface and inside the cell. The drug induces S-glutathionylation of some proteins and impacts kinase/phosphatase regulated signaling pathways. Induction of myeloproliferation is believed to contribute to the clinical advantages provided by NOV-002 that include improved tolerance of chemotherapy and increased survival.
Authors: Konjeti R Sekhar; Douglas R Spitz; Stephanie Harris; Trung T Nguyen; Michael J Meredith; Jeffrey T Holt; David Gius; Lawrence J Marnett; Marshall L Summar; Michael L Freeman; David Guis Journal: Free Radic Biol Med Date: 2002-04-01 Impact factor: 7.376
Authors: J E Ruscoe; L A Rosario; T Wang; L Gaté; P Arifoglu; C R Wolf; C J Henderson; Z Ronai; K D Tew Journal: J Pharmacol Exp Ther Date: 2001-07 Impact factor: 4.030
Authors: Judith Lahav; Eveline M Wijnen; Oded Hess; Samir W Hamaia; Delia Griffiths; Michael Makris; C Graham Knight; David W Essex; Richard W Farndale Journal: Blood Date: 2003-06-05 Impact factor: 22.113
Authors: Danyelle M Townsend; Lin He; Steven Hutchens; Tracy E Garrett; Christopher J Pazoles; Kenneth D Tew Journal: Cancer Res Date: 2008-04-15 Impact factor: 12.701
Authors: Christina L Grek; Danyelle M Townsend; Joachim D Uys; Yefim Manevich; Woodrow J Coker; Christopher J Pazoles; Kenneth D Tew Journal: Cancer Res Date: 2012-03-08 Impact factor: 12.701
Authors: J D Uys; Y Manevich; L C Devane; L He; T E Garret; C J Pazoles; K D Tew; D M Townsend Journal: Biomed Pharmacother Date: 2010-02-24 Impact factor: 6.529
Authors: A J Montero; C M Diaz-Montero; Y E Deutsch; J Hurley; L G Koniaris; T Rumboldt; S Yasir; M Jorda; E Garret-Mayer; E Avisar; J Slingerland; O Silva; C Welsh; K Schuhwerk; P Seo; M D Pegram; S Glück Journal: Breast Cancer Res Treat Date: 2011-12-03 Impact factor: 4.872
Authors: Nicola Traverso; Roberta Ricciarelli; Mariapaola Nitti; Barbara Marengo; Anna Lisa Furfaro; Maria Adelaide Pronzato; Umberto Maria Marinari; Cinzia Domenicotti Journal: Oxid Med Cell Longev Date: 2013-05-20 Impact factor: 6.543